Micafungin is a type of antifungal medicine. It's used to treat and prevent infections caused by a fungus called Candida. It works by stopping the fungus from growing.
Every report comes from a Lived member, sent anonymously.
Have you tried Micafungin for Invasive Candidiasis?
Micafungin is a prescription antifungal medicine, given through a vein, for serious infections caused by Candida, a type of yeast. It was first sold under the brand name Mycamine, which is no longer marketed in the US; micafungin is now made by several generic manufacturers. It is approved to treat Candida in the bloodstream (candidemia) and Candida infections that have spread deeper into the body, including the lining of the abdomen (peritonitis) and abscesses, which are pockets of pus. It also treats Candida infection of the esophagus, the tube that carries food to the stomach. And it is used to prevent Candida infections in people having a stem cell transplant, whose immune defenses stay very low for weeks afterward. These uses apply to adults and children 4 months and older. In younger infants it is approved for bloodstream and deep infections that have not reached the brain or eyes. Micafungin belongs to a group of antifungals called echinocandins, which infectious disease guidelines prefer as the first treatment for a confirmed Candida bloodstream infection. It is a hospital-level medicine, not a treatment for everyday yeast problems such as a vaginal yeast infection or mild mouth thrush, and it has not been shown to work against fungi other than Candida.
A yeast cell is held together by a tough outer wall, something human cells do not have. One of that wall's main building blocks is a long sugar chain called beta-glucan. Micafungin blocks the enzyme that makes beta-glucan, so the wall weakens and the yeast can no longer grow and survive. Because the drug's target exists in fungi but not in human cells, it tends to be well tolerated, even by people who are very ill. Some Candida strains carry changes in that enzyme that make micafungin less effective, and treatment failures from resistance have been reported. This is one reason the lab identifies the exact Candida species and, especially for less common species, tests which antifungals will work against it.
Micafungin is given as an intravenous (IV) infusion, a slow drip into a vein, once a day. Each infusion runs for about an hour, and it is given by a health professional, most often in the hospital. The dose depends on the purpose. In adults, the lowest daily dose is used to prevent infection during a stem cell transplant, a middle dose treats bloodstream and deep infections, and the highest dose treats esophageal infection. Children's doses are calculated from body weight. Unlike some related antifungals, micafungin does not need a larger first (loading) dose, and the dose does not change for kidney or liver problems or after dialysis. How long it continues depends on the infection and how quickly it clears. In the main clinical trials, people successfully treated for a bloodstream or esophageal infection received micafungin for about two weeks on average. For transplant prevention, it was given until white blood cell counts recovered, typically around 18 to 19 days.
The most common side effects in studies were nausea, vomiting, diarrhea, stomach pain, fever and headache. Blood tests may show lower platelet or white blood cell counts. Some people develop irritation or inflammation of the vein where the drip goes in, which happens more often with a small vein in the arm than with a central line. During or soon after an infusion, some people notice flushing, itching, a rash or facial swelling, and slowing the drip often helps. Rarely, a severe allergic reaction (anaphylaxis) occurs. Swelling of the tongue or throat, wheezing, trouble breathing or swallowing, or feeling faint during an infusion should be reported to the nurse at once so the infusion can be stopped and the reaction treated. Less often, micafungin affects the liver, the kidneys or red blood cells. Serious liver injury has been reported rarely, mostly in people who were already very ill and taking many other medicines, so liver and kidney blood tests are checked during treatment. Micafungin can also rarely cause red blood cells to break apart (hemolysis), leading to anemia. Yellowing of the skin or whites of the eyes, dark urine, or unusual tiredness or confusion should be reported to the care team right away.
Micafungin should not be given to anyone who has had an allergic reaction to it or to another echinocandin, such as caspofungin or anidulafungin. It has relatively few drug interactions. It can modestly raise blood levels of sirolimus (an anti-rejection medicine used after transplants), nifedipine (a blood pressure medicine) and itraconazole (another antifungal), so these may need closer monitoring or a lower dose. In studies it did not change levels of the anti-rejection medicines tacrolimus and cyclosporine. The care team should still know about every medicine and supplement a person takes. Animal studies suggest micafungin could harm a developing baby, and there is not enough human data to know the actual risk. Anyone who is pregnant or could be pregnant should tell the team, which will weigh this against the need to treat a serious infection. It is not known whether micafungin passes into human breast milk. One ready-to-use version comes premixed in salt solution and contains 200 to 600 mg of sodium per bag, depending on the dose. Its label advises avoiding it in people with heart failure, older adults and anyone on a sodium-restricted diet. The standard form, which the pharmacy prepares from powder, does not carry this warning.
Micafungin is usually one part of treating a serious infection. For a bloodstream infection, the care team repeats blood cultures until the yeast is gone, and a central IV line is usually removed promptly if it may be the source, because yeast can cling to the catheter and keep reseeding the blood. An eye exam is commonly done during a Candida bloodstream infection, because the yeast can settle in the eye, and if the infection persists the team may look for spread to the heart or other organs. Once a person is improving and the lab shows the yeast is susceptible, many people switch from IV micafungin to fluconazole, an antifungal pill, often after about 5 to 7 days. For a bloodstream infection without complications, antifungal treatment usually continues for 14 days after the first negative blood culture. Infections that have spread to places like the heart valves, eyes or bones need longer treatment. For esophageal infection, micafungin relieved symptoms and cleared the infection about as well as IV fluconazole in trials, and esophageal infection returning within a month was not clearly more common. Mouth and throat thrush, which most trial participants also had, did come back more often after micafungin. Returning pain or difficulty swallowing after treatment is worth reporting.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Micafungin, what you've noticed, or ask the community a question.